Global ExpansionEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada, highlighting global expansion efforts.
Patent ProtectionEsperion has reached settlements with two ANDA filers, preventing generic marketing of NEXLETOL until April 19, 2040.
Revenue GrowthRevenue continues to grow, with a 41% increase in NEXLETOL/NEXLIZET U.S. product revenue driven by retail prescription growth.